NRP1 and acute lymphoblastic leukemia: The results showed that the sensitivities of NRP‐1/CD304 for BPDCN, B‐ALL, and AML were 100.00%, 48.61%, and 4.48%, and the specificities were 87.12%, 96.01% and 82.48%, respectively (Table 2).